Interferon beta-1a Articles
Biogen Idec/ Elan reveal new Tysabri safety data
13 March 2006
Schering AG sees 2005 net leap 23%
27 February 2006
Biogen Idec sees 8% 4th-qtr 2005 sales rise
27 February 2006
Serono 4th qtr shows profit but disappoints
13 February 2006
New Zealand funds Teva's MS drug Copaxone
5 December 2005
Biogen Idec to cut 17% of jobs in response to Tysabri
19 September 2005
Biogen Idec's second-quarter EPS rises 26%
15 August 2005
Stock Commentary - Europe
1 August 2005
Serono exceeds 2nd qtr forecasts
25 July 2005
Schering AG completes enrollment in Betaferon trial
25 July 2005
BI's Avonex shows little benefit at higher doses
4 July 2005
Schering AG completes BENEFIT Ph III study in MS
27 June 2005
Serono debuts Rebif web site
27 June 2005
Stock Commentary - New York
20 June 2005
Biogen: 1st-qtr profit despite Tysabri loss
9 May 2005
Schering report strong results for MS drug Betaferon
25 April 2005
Tysabri shows strong results as add-on MS therapy
25 April 2005
One-time provisional charge blights Serono's 1st-qtr results, putting firm into a loss
22 April 2005
Serono and Syntonix: interferon inhaler deal
11 April 2005
US FDA finds no post-marketing report of PML
28 March 2005
Japan stock market week to March 21
28 March 2005
Second Tysabri trial fatality confirmed
14 March 2005
Stock Commentary - New York
7 March 2005
UPDATE: Biogen and Elan pull MS drug Tysabri from the market on two cases of CNS disorder
7 March 2005
Bioogen and Elan suspend sales of Tysabri
7 March 2005
Biogen/Elan's Tsyabri trial meets endpoint
28 February 2005
Biogen Idec boosted by Avonex
14 February 2005
Serono sees slowing 4th-qtr profits
7 February 2005
Serono completes enrollment in Rebif vs Copaxone trial
10 January 2005
Richter Gedeon's nine-month profit grows 7%
22 November 2004
Richter Gedeon's nine-month profit grows 7%
22 November 2004
Biogen's 3rd-qtr profit falls on merger costs
8 November 2004
UPDATE: Serono tops forecasts as EPS rockets 54%
1 November 2004
Serono sees 3rd-qtr net income leaps 47%
1 November 2004
Serono enters research and license deal with Zymogenetics which could exceed $100M
20 September 2004
Strong 1st-half results for Richter Gedeon
9 August 2004
Biogen Idec enters Swiss lion's den
9 August 2004
Biogen Idec closes 2nd-qtr above expectations
9 August 2004
Serono's 2nd-qtr net income jumps 26%
2 August 2004
Teva pays $5M for Active Bio's MS drug
21 June 2004
Biogen/Elan's Antegren filed for MS in USA
31 May 2004
Stock Commentary - Europe
24 May 2004
Long-term benefits of Serono's Rebif for MS
10 May 2004
Biogen Idec's 1st-qtr revenues rise 24%
10 May 2004
Serono's 1st-qtr income rockets 76.4%
26 April 2004
Positive Ph I data for Serono's cladribine
29 March 2004
SurroMed expands accord with Biogen Idec
15 March 2004
Merger costs Biogen Idec a $991M loss
8 March 2004
Stock Commentary - New York
1 March 2004
Elan/Biogen Idec's Antegren to be filed for MS early
23 February 2004
Biogen beats forecast as revenues soar
3 November 2003
Serono beats expectations with 3rd-qtr 2003 net income up 48%
3 November 2003
Biogen/Fumapharm psoriasis drug deal
13 October 2003
Long-term effect of Avonex in MS
29 September 2003
Serono raises 2003 forecast; 2nd-qtr figs
4 August 2003
Biogen's profits soar on Avonex turnover
4 August 2003
Stock Commentary - New York
30 June 2003
Scottish region's "no" to beta interferon
30 June 2003
MS postcode Rxing "still exists in UK"
12 May 2003
Serono
5 May 2003
Biogen raises forecast, shares up on news
21 April 2003
Expanded US label OKed for Betaferon
24 March 2003
Avonex to carry psychiatric warning
24 March 2003
OSI in $55M deal to sell Serono's Novantrone
17 March 2003
MS Rx costs are high but fall over time: study
17 March 2003
Biogen's earnings lower following court ruling
3 March 2003
Stock Commentary - Week to Feb 17 - Europe
24 February 2003
Study questions long-term IFN use in MS
24 February 2003
Avonex FDA-approved for use in early MS
17 February 2003
Stock Commentary - New York
10 February 2003
Update: Biogen gets US approval for Amevive
10 February 2003
Biogen to pay $55M to Schering AG
10 February 2003
Serono sees 15%-20% growth for 2003
10 February 2003
Biogen's Amevive cleared for psoriasis
10 February 2003
Biogen profits rocket in fourth quarter
3 February 2003
Biogen Japan product update
19 August 2002
Schering and Serono settle US patent dispute
29 July 2002
Biogen global sales edge up to $251M
29 July 2002
Stock Commentary - New York
22 July 2002
Stock Commentary - Europe
22 July 2002
Prempro fall-out could affect Schering AG
22 July 2002
Pfizer's muscle to support Rebif in USA
15 July 2002
Biogen links with SurroMed on MS marker research
1 July 2002
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
